Search Results - "Botta, Cirino"
-
1
AURKA targeting: a NEAT approach to halt myeloma
Published in Haematologica (Roma) (29-08-2024)“…Not available.Not available…”
Get full text
Journal Article -
2
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response
Published in Cells (Basel, Switzerland) (02-02-2021)“…New insights into the field of iron metabolism within the tumor microenvironment have been uncovered in recent years. Iron promotes the production of reactive…”
Get full text
Journal Article -
3
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells
Published in Clinical cancer research (01-03-2016)“…The onset of drug resistance is a major cause of treatment failure in multiple myeloma. Although increasing evidence is defining the role of miRNAs in…”
Get full text
Journal Article -
4
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease
Published in Journal of cellular physiology (01-07-2013)“…Skeletal homeostasis relies upon a fine tuning of osteoclast (OCL)‐mediated bone resorption and osteoblast (OBL)‐dependent bone formation. This balance is…”
Get full text
Journal Article -
5
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma
Published in Leukemia (01-03-2021)“…Multiple myeloma (MM) is tightly dependent on inflammatory bone marrow microenvironment. IL-17 producing CD4+ T cells (Th17) sustain MM cells growth and…”
Get full text
Journal Article -
6
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
Published in Leukemia (01-02-2020)“…The reason why a few myeloma cells egress from the bone marrow (BM) into peripheral blood (PB) remains unknown. Here, we investigated molecular hallmarks of…”
Get full text
Journal Article -
7
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma
Published in International journal of molecular sciences (07-05-2023)“…Primary Sjogren syndrome (pSS) is the second most common autoimmune disorder worldwide, which, in the worst scenario, progresses to Non-Hodgkin Lymphoma (NHL)…”
Get full text
Journal Article -
8
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility
Published in Journal of translational medicine (17-02-2021)“…The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical and laboratory predictors of the progression towards…”
Get full text
Journal Article -
9
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
Published in Oncotarget (29-09-2015)“…miR-21 is an oncogenic microRNA (miRNA) with an emerging role as therapeutic target in human malignancies, including multiple myeloma (MM). Here we…”
Get full text
Journal Article -
10
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
Published in Cancers (28-06-2021)“…Multiple myeloma (MM) is the second most common hematologic malignancy, characterized by a multi-step evolutionary path, which starts with an early…”
Get full text
Journal Article -
11
Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant eligible newly diagnosed multiple myeloma: a multicentre real-world experience
Published in Haematologica (Roma) (31-10-2024)“…Not available.Not available…”
Get full text
Journal Article -
12
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials
Published in International journal of molecular sciences (01-06-2023)“…The treatment of chronic lymphocytic leukemia (CLL) currently relies on the use of chemo-immunotherapy, Bruton's tyrosine kinase inhibitors, or BCL2 inhibitors…”
Get full text
Journal Article -
13
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome
Published in International journal of molecular sciences (16-05-2023)“…Multiple myeloma (MM) is a hematologic malignancy with a multistep evolutionary pattern, in which the pro-inflammatory and immunosuppressive microenvironment…”
Get full text
Journal Article -
14
Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune–Biological Evaluation and Case Report
Published in International journal of molecular sciences (10-06-2021)“…Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by…”
Get full text
Journal Article -
15
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients
Published in Cancer biology & therapy (10-06-2013)“…Bevacizumab is a humanized anti-VEGF monoclonal antibody able to produce clinical benefit in advanced non-squamous non-small-cell lung cancer (NSCLC) patients…”
Get full text
Journal Article -
16
Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing
Published in Cell death & disease (16-06-2021)“…Motoneuronal loss is the main feature of amyotrophic lateral sclerosis, although pathogenesis is extremely complex involving both neural and muscle cells. In…”
Get full text
Journal Article -
17
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
Published in Frontiers in oncology (14-04-2021)Get full text
Journal Article -
18
Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Published in Current cancer drug targets (01-01-2017)“…Multiple myeloma (MM) is an incurable plasma cell neoplasm accounting for about 10% of all hematologic malignancies. Recently, emerging evidence is disclosing…”
Get more information
Journal Article -
19
COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm
Published in Frontiers in oncology (08-01-2021)“…Since SARS-CoV-2 outbreak in December 2019, world health-system has been severely impacted with increased hospitalization, Intensive-Care-Unit (ICU) access and…”
Get full text
Journal Article -
20
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients
Published in Blood advances (28-02-2017)“…Despite major therapeutic advancements, multiple myeloma (MM) is still incurable and relapsed/refractory multiple myeloma (RRMM) remains a challenge; the…”
Get full text
Journal Article